[go: up one dir, main page]

WO2008044261A1 - Utilisation de l'amiodarone et d'analogues de l'amiodarone en tant qu'agents antiviraux - Google Patents

Utilisation de l'amiodarone et d'analogues de l'amiodarone en tant qu'agents antiviraux Download PDF

Info

Publication number
WO2008044261A1
WO2008044261A1 PCT/IT2007/000712 IT2007000712W WO2008044261A1 WO 2008044261 A1 WO2008044261 A1 WO 2008044261A1 IT 2007000712 W IT2007000712 W IT 2007000712W WO 2008044261 A1 WO2008044261 A1 WO 2008044261A1
Authority
WO
WIPO (PCT)
Prior art keywords
amiodarone
virus
use according
preparations
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2007/000712
Other languages
English (en)
Inventor
Aldo Baritussio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Padova
Original Assignee
Universita degli Studi di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Padova filed Critical Universita degli Studi di Padova
Publication of WO2008044261A1 publication Critical patent/WO2008044261A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • Biogenesis and proper functioning of late compartments of the endocytic pathway depend on a highly conserved set of proteins (Hrs, ESCRT I-III, Alix) that assemble on the cytoplasmic side of early endosomes and make them mature into late endosomes/multivesicular bodies (Slagsvold T. et al Trends Cell Biol 2006; 16: 317-326; Williams RL et al Nature Rev Cell Biol 2007;8:355368).
  • Vero cells take up amiodarone at a speed comparable to that of alveolar macrophages, as shown in the following table in which Vero cells and macrophages were exposed for 1 hour to trace concentrations of 125 I-amiodarone.
  • amiodarone might interfere with the assembly of structural proteins and genomic RNA into new virions or might inhibit the release of progeny virus in the extracellular space, since the protein complexes necessary for the biogenesis of multivesicular bodies mediate also virus budding (Slagsvold T et al. Trends Cell Biol 2006; 16:317-326). Furthermore it is still possible that the antiviral effects of amiodarone could be occurring both at a post endosomal level and in the endosomes.
  • An attractive aspect of the present findings is that amiodarone appears to act against the virus through modifications of the target cell and thus its activity is theoretically less exposed to the effects of viral mutations (Savarino A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de l'amiodarone, et de composés structurellement apparentés, en tant qu'agents antiviraux. L'amiodarone, qui est largement utilisée pour traiter les arythmies cardiaques, inhibe la propagation in vitro du coronavirus, responsable du syndrome respiratoire aigu sévère (SRAS), par son action postérieure à l'introduction du génome viral dans le cytoplasme. L'effet antiviral de l'amiodarone semble être associé aux modifications se produisant dans la cellule hôte plutôt qu'à un effet direct sur le coronavirus du SRAS, et il se produit à des concentrations proches de celles obtenues chez des patients traités pour une arythmie. Bien que le mécanisme subtil de l'activité antivirale reste à éclaircir, les préparations pharmaceutiques contenant de l'amiodarone ou des composés structurellement apparentés pourraient être utilisées pour le traitement ou la prévention d'infections causées par le coronavirus du SRAS ou par des virus présentant des modes similaires d'infection.
PCT/IT2007/000712 2006-10-12 2007-10-11 Utilisation de l'amiodarone et d'analogues de l'amiodarone en tant qu'agents antiviraux Ceased WO2008044261A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITPD2006A000380 2006-10-12
IT000380A ITPD20060380A1 (it) 2006-10-12 2006-10-12 Uso di amiodarone e suoi analoghi come agenti antivirali

Publications (1)

Publication Number Publication Date
WO2008044261A1 true WO2008044261A1 (fr) 2008-04-17

Family

ID=38887350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000712 Ceased WO2008044261A1 (fr) 2006-10-12 2007-10-11 Utilisation de l'amiodarone et d'analogues de l'amiodarone en tant qu'agents antiviraux

Country Status (2)

Country Link
IT (1) ITPD20060380A1 (fr)
WO (1) WO2008044261A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410167B2 (en) 2008-04-17 2013-04-02 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GEISBERT T W ET AL: "Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 362, no. 9400, 13 December 2003 (2003-12-13), pages 1953 - 1958, XP004480590, ISSN: 0140-6736 *
ITO H ET AL: "Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice", CYTOKINE 2002 UNITED KINGDOM, vol. 17, no. 4, 2002, pages 197 - 202, XP002465674, ISSN: 1043-4666 *
LAI S T: "Treatment of severe acute respiratory syndrome", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES 2005 GERMANY, vol. 24, no. 9, 2005, pages 583 - 591, XP002465673, ISSN: 0934-9723 *
MOELLER MAREN ET AL: "Antibacterial, antiviral, anti proliferative and apoptosis-inducing properties of Brackenridgea zanguebarica (Ochnaceae)", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 58, no. 8, August 2006 (2006-08-01), pages 1131 - 1138, XP008087731, ISSN: 0022-3573 *
YUSA KEISUKE ET AL: "Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 25, no. 1, 1994, pages 57 - 66, XP008087736, ISSN: 0166-3542 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410167B2 (en) 2008-04-17 2013-04-02 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US9107900B2 (en) 2008-04-17 2015-08-18 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Also Published As

Publication number Publication date
ITPD20060380A1 (it) 2008-04-13

Similar Documents

Publication Publication Date Title
Shen et al. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections
Mahmoud et al. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention
EP3697404B1 (fr) Compositions et méthodes pour thérapie antivirale à large spectre
Waarts et al. Antiviral activity of human lactoferrin: Inhibition of alphavirus interaction with heparan sulfate
JP2023513436A (ja) ２０１９新型コロナウイルス（２０１９－ｎＣｏＶ）によって引き起こされる重症急性呼吸器感染症の治療のためのＲＮＡｉ予防治療薬組成物及び方法
US20220047545A1 (en) Micronutrient combination to inhibit coronavirus cell infection
US11419847B2 (en) Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants
Kathiravan et al. An overview of spike surface glycoprotein in severe acute respiratory syndrome–coronavirus
WO2008044261A1 (fr) Utilisation de l'amiodarone et d'analogues de l'amiodarone en tant qu'agents antiviraux
Sreelatha et al. Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis
CA3169528A1 (fr) Pld s'utilisant en combinaison dans le traitement de coronavirus
KR20150048132A (ko) 바이러스성 질환을 치료하기 위한 헤테로시클릴 카르복스아미드
WO2022117724A1 (fr) Inhibiteurs de cystéine protéase à base de 8-hydroxyquinoléine destinés à être utilisés dans la prévention et/ou le traitement d'une maladie à coronavirus
Nitschke et al. Equine arteritis virus is delivered to an acidic compartment of host cells via clathrin-dependent endocytosis
Leowattana COVID-19: Potential repurposing drugs
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
CA3238128A1 (fr) Nouvelles compositions antivirales comprenant de l'acide oleique
US20230172906A1 (en) Method to treat viral infection induced by a coronavirus
WO2022173456A1 (fr) Composition pharmaceutique de micronutriments et son utilisation pour inhiber simultanément de multiples mécanismes cellulaires d'infectivité provoqués par un coronavirus, ses variants et mutants
US20220304947A1 (en) Compositions and methods for inhibiting proteolytic activation of viruses
FR3108033A1 (fr) COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2
Hewedy Broad-Spectrum Antivirals to Combat COVID-19: the Reality and Challenges
WO2022112399A1 (fr) Compositions pour l'inactivation de sars-cov-2
WO2023059809A2 (fr) Méthodes et agents pour la prévention de la prolifération virale
EP4064861A1 (fr) Composition pharmaceutique de micronutriments et son utilisation pour inhiber simultanément de multiples mécanismes cellulaires d'infectivité provoqués par un coronavirus, ses variants et mutants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827763

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827763

Country of ref document: EP

Kind code of ref document: A1